Interview with Bertrand Baron, CEO, Sanofi Mexico
Sanofi acquired Kendrick in 2009. Obviously the thinking behind it was to diversify your products into pure generics, but what were the expectations for the move? We have a diversified…
Address: Av. Universidad N° 1738
Col. Coyoacán
04000 México, D.F.
Tel: 54 84 44 00
Web: http://www.sanofi.com.mx/l/mx/sp/index.jsp
Present in more than 100 countries, with around 11,000 scientists, Sanofi has around 100,000 employees working to improve health and wellbeing. Sanofi’s global headquarters are in Paris, France. Sanofi in Mexico counts on nine major therapeutic areas and its own line of generic medicines.
Sanofi focuses its activities on 9 major therapeutic areas: Cardiovascular, Thrombosis, Diabetes, Oncology, Central Nervous System, Internal Medicine, Vaccines, OTC and Personal Health Care
Sanofi acquired Kendrick in 2009. Obviously the thinking behind it was to diversify your products into pure generics, but what were the expectations for the move? We have a diversified…
Consuelo Albarrán, co-founder and CEO of DEFI Latina Healthcare, showcases the increasing added value brought by this leading Cofepris-authorized third party (ATP) to the pharmaceutical industry, the recent expansion of…
Rodrigo Puga, the recently appointed general manager of Pfizer Mexico, documents his strategic priorities to further strengthen the company’s performance in Mexico and consolidate Pfizer’s leadership within the Mexican market…
General Manager of Merck Mexico, Pedro Galvis, showcases the strategic importance of the Mexican affiliate within Merck’s global network and explains the importance of public-private partnerships in enhancing patient access and…
Paulina Escobedo, general manager of B. Braun Medical Mexico, provides insights into the impressive development of this division since it was set up in the country in 2011, while the…
The university spin-off UDIBI continues its unstoppable ascension: after being recently recognized by Cofepris, Mexico’s sanitary agency, as an authorized laboratory to assess biotech treatments entering the Mexican market, UDIBI…
Alexis Serlin, country president of Novartis Mexico and president of CANIFARMA, the industry chamber that brings together multinational and local drug manufacturers, explains how the pharmaceutical industry in Mexico aims…
The General Directors of Rayere explain how the historical Mexican pharma company has been leveraging its outstanding manufacturing capacity and product development expertise to become a thriving and reputed player…
Carlos Abelleyra Cordero, CEO Spanish Latin America of Aspen Labs, describes the rapid development of Aspen’s operational capacity throughout the region, in line with the company’s ambition to ultimately establish…
Karel Fucikovsky, general director PFM Latin America at Pierre Fabre, on the strategic focus of the company on operational and commercial excellence in Mexico and Latin America, which both stand as…
In an exclusive interview, Dr. José Narro Robles, Secretary of Health of Mexico, provides insight into the main challenges of the domestic healthcare system and his strategic priorities to improve…
Takeda Mexico’s José Manuel Caamaño discusses Takeda’s impressive growth prospects in Mexico, patient-centricity, the reopening of their cutting-edge manufacturing plant in Naucalpan, and his vision to transform Takeda into one…
José Reyes Baeza Terrazas, general director of ISSSTE (Institute for Social Security and Services for State Workers) documents some of the institution’s key specificities that make it one of the…
See our Cookie Privacy Policy Here
